

# NEW ZEALAND DATA SHEET

## 1. PRODUCT NAME

Anzatax™ 6 mg/mL Concentrate for injection.

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Anzatax Injection Concentrate contains 6 mg/mL paclitaxel.

### Excipient(s) with known effect

- Ethanol

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Anzatax is a concentrate for injection. It is a sterile, clear to pale yellow solution and free of visible particles. Anzatax Injection Concentrate has a pH of 6 to 7.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

Anzatax Injection Concentrate is indicated for the primary treatment of ovarian cancer in combination with a platinum agent.

Anzatax Injection Concentrate is indicated for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy.

Anzatax Injection Concentrate is indicated for the treatment of non-small cell lung cancer (NSCLC).

Anzatax Injection Concentrate is indicated for adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.

Anzatax Injection Concentrate is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab, in patients who have tumours that over-express HER-2 and who have not received previous chemotherapy for their metastatic disease.

### 4.2 Dose and method of administration

All patients should be premedicated before paclitaxel is administered to prevent severe hypersensitivity reactions (see section 4.4). Before every treatment cycle patients should be premedicated with:

- dexamethasone 20 mg orally 12 hours and 6 hours prior to starting the paclitaxel infusion.

- promethazine 25 mg to 50 mg intravenously or other suitable H<sub>1</sub>-antagonist, 30 minutes prior to starting the paclitaxel infusion.
- ranitidine 50 mg by intravenous infusion over 15 minutes, starting 30 minutes prior to the paclitaxel infusion.

For primary treatment of ovarian cancer, it is recommended that paclitaxel be used at a dose of:

- 175 mg/m<sup>2</sup>, administered intravenously over 3 hours, followed by cisplatin 75 mg/m<sup>2</sup>. The infusion should be repeated every three weeks.
- 135 mg/m<sup>2</sup> administered intravenously over 24 hours, followed by cisplatin 75 mg/m<sup>2</sup>. The infusion should be repeated every three weeks.

For the treatment of metastatic ovarian cancer or metastatic breast cancer, it is recommended that paclitaxel be used as a single agent at a dose of 175 mg/m<sup>2</sup>. Paclitaxel should be administered as an intravenous infusion over 3 hours. The infusion should be repeated every 3 weeks as tolerated. Patients have tolerated treatment with up to 9 cycles of paclitaxel therapy, but the optimal course of therapy remains to be established.

For primary or secondary treatment of NSCLC, the recommended dose of paclitaxel is 175 mg/m<sup>2</sup> administered intravenously over 3 hours with a 3 week interval between courses.

For node-positive breast cancer, the recommended dose of paclitaxel is 175 mg/m<sup>2</sup> administered intravenously over 3 hours every 3 weeks for four courses following doxorubicin and cyclophosphamide combination therapy.

For over-expression of HER-2 breast cancer, paclitaxel 175 mg/m<sup>2</sup> administered intravenously over 3 hours with a 3 week interval between courses for six cycles. Trastuzumab 2 mg/kg administered intravenously once a week until progression of disease after an initial loading dose of 4 mg/kg body weight. Paclitaxel infusion may be started the day following the first dose of trastuzumab or immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.

### **Dose adjustment**

Subsequent doses of paclitaxel should be administered according to individual patient tolerance. Repetition of a course of paclitaxel is not recommended until the patient's neutrophil count is at least 1.5 x 10<sup>9</sup> cells/L (1,500 cells/mm<sup>3</sup>) and the platelet count is at least 100 x 10<sup>9</sup> cells/L (100,000 cells/mm<sup>3</sup>). If there is severe neutropenia (neutrophil count less than 0.5 x 10<sup>9</sup> cells/L for a minimum of 7 days) or severe peripheral neuropathy or severe mucositis during paclitaxel therapy, the dose of paclitaxel in subsequent courses should be reduced by 20% (see section 4.4). The incidence of neurotoxicity and the severity of neutropenia increase with dose within a regime.

### **Hepatic impairment**

Inadequate data are available to recommend dosage alterations in patients with mild, moderate and severe hepatic impairments (see section 4.4).

### Paediatric population

Paclitaxel is not recommended for use in children below 18 years due to lack of data on safety and efficacy (see section 4.4).

### **Dilution**

Anzatax Injection Concentrate **MUST BE DILUTED PRIOR TO INTRAVENOUS INFUSION**. It should be diluted in 5% glucose or 0.9% sodium chloride intravenous infusion.

Dilution should be made to a final concentration of 0.3 to 1.2 mg/mL.

After the final dilution of Anzatax Injection Concentrate, the bottle should be swirled gently to disperse the paclitaxel. **DO NOT SHAKE**.

Avoid contact of paclitaxel solutions with plasticised polyvinyl chloride (PVC) equipment, infusion lines or devices used when preparing infusion solutions. Prepare and store diluted paclitaxel solutions in glass bottles or non-PVC infusion bags. These precautions are to avoid leaching of the plasticiser DEHP (di-[2-ethylhexyl] phthalate) from PVC infusion bags or sets. Paclitaxel solutions should be administered through polyethylene lined administration sets (e.g. Gemini 20 giving set), using an IMED<sup>®</sup> pump.

Although solutions of paclitaxel for infusion prepared as outlined above are chemically stable for 3 days at room temperature (25°C) and 14 days at 2°C to 8°C, it is recommended that the solution for infusion should be administered immediately after preparation as it does not contain an antimicrobial agent. The infusion should be completed within 24 hours of preparation of the solution and any residue discarded, according to the guidelines for the disposal of cytotoxic drugs (see section 6.6). Use in one patient on one occasion only.

Compounding centres which:

1. are licensed by Medsafe to reconstitute and/or further dilute cytotoxic products; and
2. have validated aseptic procedure and regular monitoring of aseptic technique may apply the following shelf lives when stored under the specified conditions:

Diluent	Stored Below 25°C		Stored at 2°C to 8°C (Refrigerate. Do not freeze)	
	Non-PVC Infusion Bag	Glass Bottle	Non-PVC Infusion Bag	Glass Bottle
0.9% Sodium Chloride for Intravenous Infusion	7 days	3 days	28 days	14 days
5% Glucose for Intravenous Infusion	7 days	3 days	14 days	14 days

Solutions prepared this way have been shown to be chemically stable for these periods. Administration should be completed within 24 hours of the start of the infusion and any residue discarded according to the guidelines for the disposal of cytotoxic drugs. Do not use paclitaxel if any precipitation forms or if the diluted solution appears cloudy.

## **Filtration**

A microporous membrane of 0.22 microns or less in size is recommended as the in-line filter for all infusions of paclitaxel. The IMED<sup>®</sup> 0.2 micron add on filter set composed of polysulfone and the IVEX<sup>™</sup> II 0.2 micron filter composed of cellulose have both been found to be suitable for Anzatax Injection Concentrate.

## **4.3 Contraindications**

Anzatax Injection Concentrate must not be used in patients who have exhibited hypersensitivity reactions to paclitaxel or other taxanes.

Anzatax Injection Concentrate must not be used in patients who have a history of hypersensitivity reactions to polyoxylated (PEG-35) castor oil or drugs formulated in PEG-35 castor oil (e.g. ciclosporin for injection concentrate and teniposide for injection concentrate) or any of the other excipients.

Anzatax Injection Concentrate should not be administered in patients who have a baseline neutrophil count of  $<1.5 \times 10^9$  cells/L.

## **4.4 Special warnings and precautions for use**

### **General**

Paclitaxel should be administered under the supervision of a physician experienced in the use of chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Paclitaxel should be given before a platinum compound when it is given in combination with a platinum compound.

### **Premedication**

In order to minimise the possibility of hypersensitivity reactions due to histamine release, patients should be premedicated before every treatment cycle of paclitaxel. Premedication should include corticosteroids (e.g. dexamethasone), antihistamines (e.g. diphenhydramine or promethazine) and an H<sub>2</sub>-receptor antagonist (e.g. ranitidine) (see section 4.2). The characteristic symptoms of hypersensitivity reactions are dyspnoea and hypotension both requiring treatment, angioedema and widespread urticaria. In clinical trials, 2% of patients treated with paclitaxel experienced severe hypersensitivity. One of these reactions was fatal in a patient treated without premedication. Anzatax Injection Concentrate must not be used in patients who have exhibited hypersensitivity reactions to paclitaxel.

### **Administration**

Paclitaxel is administered by intravenous infusion only; it must not be administered by the intracerebral, intrapleural or intraperitoneal routes. Anzatax Injection Concentrate must be diluted before intravenous infusion. Prior to intravenous infusion of paclitaxel, it must be ensured that the indwelling catheter is in the correct position as extravasation, necrosis and/or thrombophlebitis may result with incorrect administration (see section 4.2).

Patients receiving paclitaxel should be under continuous observation for at least the first 30 minutes following the start of the infusion and frequently thereafter. In case of a severe hypersensitivity reaction, paclitaxel infusion should be discontinued immediately and appropriate treatment given as indicated for anaphylaxis. The patient should not be rechallenged with the drug. Minor hypersensitivity reactions such as flushing, skin reactions, etc, do not require interruption of therapy (see also section 4.8).

In some patients, temporary discontinuation of the infusion is sufficient to resolve the symptoms. Other patients may require therapy with bronchodilators, adrenaline, antihistamines and corticosteroids, either alone or in combination.

### **Renal and hepatic impairment**

The effect of renal and/or hepatic impairment on the pharmacokinetics of paclitaxel has not been established. However, as the liver is thought to be the primary site for metabolism of the drug, paclitaxel should be given cautiously to patients with decreased liver function. Paclitaxel has been shown to cause a dose-related elevation of liver enzymes.

Patients with hepatic impairment may be at increased risk of toxicity, particularly Grade 3-4 myelosuppression. There is no evidence that the toxicity of paclitaxel is increased when given as a 3 hour infusion to patients with mildly abnormal liver function. When paclitaxel is given as a greater than 3 hour infusion, increased myelosuppression may be seen in patients with moderate to severe hepatic impairment. Inadequate data are available to recommend dosage alterations in patients with mild to moderate hepatic impairments (see section 5.2). Patients with severe hepatic impairment must not be treated with paclitaxel.

### **Cardiovascular toxicity**

Hypotension, hypertension and bradycardia have been observed during paclitaxel administration, but generally do not require treatment. Frequent monitoring of vital signs, particular during the first hours of paclitaxel infusion is recommended (see also section 4.8).

Electrocardiographic monitoring is recommended for patients with serious conduction abnormalities and should be commenced for patients who develop abnormal cardiovascular symptoms or signs during monitoring of vital signs.

Severe cardiac conduction abnormalities have been reported rarely during paclitaxel therapy. If patients develop significant conduction abnormalities during paclitaxel administration, appropriate therapy should be administered and continuous electrocardiographic monitoring should be commenced and performed during subsequent therapy with paclitaxel (see section 4.8). Severe cardiovascular events were observed more frequently in patients with NSCLC than breast or ovarian cancer.

When paclitaxel is used in combination with trastuzumab or doxorubicin for treatment of metastatic breast cancer, monitoring of cardiac function is recommended. When patients are candidates for treatment with paclitaxel in these combinations, they should undergo baseline cardiac assessment including history, physical examination, ECG, echocardiogram, and/or multi-gated radionuclide angiography (MUGA) scan. Cardiac function should be further monitored during treatment (e.g., every 3 months). Monitoring may help to identify patients who develop cardiac dysfunction and treating physicians should carefully assess the cumulative dose ( $\text{mg}/\text{m}^2$ ) of anthracycline administered when making decisions regarding frequency of

ventricular function assessment. When testing indicates deterioration in cardiac function, even asymptomatic, treating physicians should carefully assess the clinical benefits of further therapy against the potential for producing cardiac damage, including potentially irreversible damage. If further treatment is administered, monitoring of cardiac function should be more frequent (e.g. every 1-2 cycles).

### **Nervous system**

Patients with pre-existing neuropathy should be carefully monitored. Peripheral neuropathy is frequently reported in patients receiving paclitaxel and the severity is dose-dependent. A 20% reduction in paclitaxel dose for all subsequent courses is recommended for patients who develop severe peripheral neuropathy during therapy (see section 4.8).

In NSCLC patients, the administration of paclitaxel in combination with cisplatin resulted in a greater incidence of neurotoxicity than usually seen in patients receiving single agent paclitaxel.

Paclitaxel contains ethanol, 396 mg/mL; consideration should be given to possible CNS and other effects of alcohol.

Children may be more sensitive than adults to the effects of ethanol.

### **Neutropenia (see section 4.8)**

As the dose-limiting toxicity of paclitaxel is dose-related bone-marrow suppression (primarily neutropenia), paclitaxel should not be given to patients with a pre-treatment neutrophil count of less than  $1.5 \times 10^9$  cells/L ( $1,500$  cells/mm<sup>3</sup>) or platelet count of less than  $100 \times 10^9$  cells/L. Blood counts should be frequently monitored during treatment with paclitaxel. Further cycles of paclitaxel should not be administered until the patient's neutrophil count is greater than  $1.5 \times 10^9$  cells/L ( $1,500$  cells/mm<sup>3</sup>) and the platelet count is greater than  $100 \times 10^9$  cells/L ( $100,000$  cells/mm<sup>3</sup>).

If there is severe neutropenia during a course of paclitaxel (i.e. neutrophil count less than  $0.5 \times 10^9$  cells/L ( $500$  cells/mm<sup>3</sup>) for 7 or more days), the dose of paclitaxel in subsequent cycles should be reduced by 20%. Previous radiation therapy may induce more severe myelosuppression. There is little information available from such patients at doses above  $135$  mg/m<sup>2</sup>.

### **Anaphylaxis and severe hypersensitivity reactions**

Severe hypersensitivity (anaphylactoid reactions characterised by dyspnoea and hypotension requiring treatment, angioedema and generalised urticaria have occurred rarely in premedicated patients receiving paclitaxel. Rare fatal reactions have occurred in patients despite pre-treatment. Cross-hypersensitivity between ANZATAX and other taxane products has been reported and may include severe reactions such as anaphylaxis. Patients with a previous history of hypersensitivity to other taxanes should be closely monitored during initiation of ANZATAX therapy.

Since significant hypersensitivity reactions may occur, appropriate supportive equipment should be available. Patients receiving paclitaxel should be under continuous observation for at least the first 30 mins following the start of the infusion and frequently thereafter. In case of a severe hypersensitivity reaction, paclitaxel infusion should be discontinued immediately

and appropriate treatment given as indicated for anaphylaxis. The patient should not be rechallenged with the drug. Minor hypersensitivity reactions such as flushing, skin reactions, etc do not require interruption of therapy (see also section 4.8).

### **Gastrointestinal**

In patients receiving paclitaxel who complain of abdominal pain with other signs and symptoms, bowel perforation should be excluded.

### **Injection site reaction**

A specific treatment for extravasation reaction is unknown at this time. Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.

### **Interstitial pneumonia**

Paclitaxel in combination with radiation of the lung, irrespective of their chronological order, may contribute to the development of interstitial pneumonia.

### **Pseudomembranous colitis**

Pseudomembranous colitis has been reported in patients who have not been concomitantly treated with antibiotics. This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel.

### **Mucositis**

Severe mucositis has been reported which requires dose reduction (see section 4.2).

### **Ophthalmology**

There have been reports of reduced visual acuity due to cystoid macular oedema (CMO) during treatment with paclitaxel as well as with other taxanes (see section 4.8). Patients with visual impairment during paclitaxel treatment should seek a prompt and complete ophthalmologic examination. Paclitaxel should be discontinued if a CMO diagnosis is confirmed.

### **Use in the elderly**

Of 2228 patients who received paclitaxel in eight clinical studies evaluating its safety and efficacy in the treatment of advanced ovarian cancer, breast carcinoma or NSCLC and 1570 patients who were randomised to receive paclitaxel in the adjuvant breast cancer study, 649 patients (17%) were 65 years or older, including 49 patients (1%) 75 years or older. In most studies, severe myelosuppression was more frequent in elderly patients; in some studies, severe neuropathy was more common in elderly patients. In two clinical studies in NSCLC, the elderly patients treated with paclitaxel had a higher incidence of cardiovascular events. Estimates of efficacy appeared similar in elderly patients and in younger patients; however, comparative efficacy cannot be determined with confidence due to the small number of elderly patients studied. In a study of first line treatment of ovarian cancer, elderly patients had a lower

median survival than younger patients, but no other efficacy parameters favoured the younger group.

### **Paediatric population**

The safety and effectiveness of Anzatax Injection Concentrate in children has not been established. It should be noted that children may be more sensitive than adults to the effects of ethanol. There have been reports of central nervous system (CNS) toxicity (rarely associated with death) in a clinical trial in paediatric patients in which paclitaxel was infused intravenously over 3 hours at doses ranging from 350 mg/m<sup>2</sup> to 420 mg/m<sup>2</sup>. The toxicity is most likely attributable to the high dose of the ethanol component of the paclitaxel vehicle given over a short infusion time. The use of concomitant antihistamines may intensify this effect. Although a direct effect of the paclitaxel itself cannot be discounted, the high doses used in this study (over twice the recommended adult dosage) must be considered in assessing the safety of paclitaxel for use in this population.

## **4.5 Interaction with other medicines and other forms of interaction**

**Cisplatin:** The recommended regimen of paclitaxel administration for the first-line chemotherapy of ovarian carcinoma is for paclitaxel to be given before cisplatin. When paclitaxel is given before cisplatin, the safety profile of paclitaxel is consistent with that reported for single-agent use. Administration of cisplatin prior to paclitaxel treatment leads to greater myelosuppression than that seen when paclitaxel is given prior to cisplatin. In patients receiving cisplatin prior to paclitaxel, there is about a 20% decrease in paclitaxel clearance. Patients treated with paclitaxel and cisplatin may have an increased risk of renal failure as compared to cisplatin alone in gynecological cancers.

**Doxorubicin:** Sequence effects characterised by more profound neutropenic and stomatitis episodes have been observed with combination use of paclitaxel and doxorubicin when paclitaxel was administered before doxorubicin and using longer than recommended infusion times (paclitaxel administered over 24 hours; doxorubicin over 48 hours). Plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination and are given closer in time. Paclitaxel for initial treatment of metastatic breast cancer should be administered 24 hours after doxorubicin (see section 4.2). However, data from a trial using bolus doxorubicin and 3-hour paclitaxel infusion found no sequence effects on the pattern of toxicity.

**Drugs metabolised in the liver:** The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and 3A4. Clinical studies have demonstrated that CYP2C8 mediated metabolism of paclitaxel, to 6 $\alpha$ -hydroxypaclitaxel, is the major metabolic pathway in humans. Concurrent administration of ketoconazole, a known potent inhibitor of CYP3A4, does not inhibit the elimination of paclitaxel in patients; thus, both medicinal products may be administered together without dosage adjustment. Further data on the potential of drug interactions between paclitaxel and CYP2C8 and 3A4 substrates/inhibitors are limited. Therefore, caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit (e.g. erythromycin, fluoxetine, gemfibrozil, deferasirox, trimethoprim) or induce (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz, nevirapine, St John's wort) either CYP2C8 or 3A4.

In the clinical trial of paclitaxel in combination with trastuzumab, mean serum trough concentrations of trastuzumab were consistently elevated 1.5 fold as compared with serum concentrations of trastuzumab in combination with anthracycline plus cyclophosphamide (AC).

Arthralgia or myalgia adverse events of paclitaxel appear to be of a higher incidence in patients being treated concurrently with filgrastim (granulocyte colony stimulating factor; G-CSF).

## **4.6 Fertility, pregnancy and lactation**

### **Fertility**

See section 5.3.

#### Infertility in Females and Males

Based on findings in animal studies, ANZATAX may impair fertility in females and males of reproductive potential. Male patients should seek advice regarding cryoconservation of sperm prior to treatment with paclitaxel because of the possibility of infertility. It is also recommended to discuss fertility preservation with female patients prior to treatment.

### **Pregnancy - Category D**

Paclitaxel is a cytotoxic agent that can produce spontaneous abortion, fetal loss and birth defects and may cause fetal harm when administered to a pregnant woman. Therefore, paclitaxel should not be used during pregnancy unless clearly necessary.

Studies have shown paclitaxel to be toxic to embryos and fetuses in rabbits at an intravenous dose of 3 mg/kg (33 mg/m<sup>2</sup>) given during organogenesis. Paclitaxel is toxic to rat fetuses at a dose of 1 mg/kg (6 mg/m<sup>2</sup>) and produced low fertility and fetal toxicity in rats. Examination revealed that no gross external, soft tissue or skeletal alterations occurred.

There are no studies in pregnant women. Women of childbearing potential should have a pregnancy test prior to starting treatment with ANZATAX. If paclitaxel is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard.

#### Females and Males of Reproductive Potential

##### *Males*

Based on findings in genetic toxicity and animal reproduction studies, male patients with female partners of childbearing potential should be advised to use effective contraception in order to avoid fathering a child during treatment and for at least four months after the last dose of ANZATAX.

##### *Females*

Due to the potential for genotoxicity, female patients of childbearing potential should be advised to use effective contraception in order to avoid becoming pregnant during treatment and for at least seven months after the last dose of ANZATAX.

## **Lactation**

Based on published case reports from three women, paclitaxel has been detected in breastmilk after administration. Because of the potential for serious adverse reactions due to paclitaxel in nursing infants, the mother should be advised not to breastfeed while on paclitaxel therapy and for 2 weeks following the last dose of treatment.

## **4.7 Effects on ability to drive and use machinery**

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration. Anzatax Injection Concentrate is likely to produce minor or moderate adverse effects, which may impair the patient's ability to concentrate and react and therefore constitute a risk in the ability to drive and use machines. Patients should refrain from driving or using machines until they know that paclitaxel does not negatively affect these abilities. It should be noted that paclitaxel contains ethanol.

## **4.8 Undesirable effects**

The following is based on the experience of 812 patients treated in Phase II and III clinical trials. The frequency and severity of adverse effects are generally similar between patients receiving paclitaxel for the treatment of ovarian, breast or lung cancer. None of the observed effects were clearly influenced by age. Unless stated otherwise, percent figures, where given, are based on observed incidence when using the recommended dosing regime. If other regimes are used, the incidence of reaction may be higher.

Safety of the paclitaxel/platinum combination has been investigated in a large randomised trial in ovarian cancer and in two Phase III trials in NSCLC. Unless otherwise mentioned, the combination of paclitaxel with platinum agents did not result in any clinically relevant changes to the safety profile of single agent paclitaxel.

Adverse effects reported were those occurring during or following the first course of therapy, and have, where possible, been grouped by frequency according to the following criteria.

*Very common:*  $\geq 1/10$

*Common:*  $\geq 1/100$  and  $< 1/10$

*Uncommon:*  $\geq 1/1000$  and  $< 1/100$

*Rare:*  $\geq 1/10000$  and  $< 1/1000$

*Very rare:*  $< 1/10000$

## **Cardiovascular**

*Very common:* Hypotension.

*Common:* Bradycardia; ECG abnormalities (non-specific repolarisation and sinus tachycardia).

*Uncommon:* ECG abnormalities (premature beats), cardiomyopathy.

*Rare:* Myocardial infarction; congestive heart failure (typically in patients who have received other chemotherapy, notably anthracyclines).

Six severe cardiovascular events possibly related to paclitaxel administration occurred including asymptomatic ventricular tachycardia, tachycardia with bigeminy, atrioventricular block (2 patients), and syncopal episodes (2 patients - in one associated with severe hypotension and coronary stenosis resulting in death). Severe hypotensive reactions have been associated with serious hypersensitivity reactions and have required intervention. Cardiac failure and sinus bradycardia have also been observed.

## **Haematological**

*Very common:* Myelosuppression, thrombocytopenia, leucopenia, fever, bleeding, anaemia; neutropenia (overall, 52% of the patients experienced severe Grade IV neutropenia and 56% had Grade III/IV severe neutropenia on their first course. Neutrophil nadirs occurred at a median of 11 days after paclitaxel administration).

*Common:* Febrile neutropenia (associated with an infectious episode, including UTI and URTI).

*Rare:* Five septic episodes, which were associated with severe neutropenia attributable to paclitaxel administration had a fatal outcome.

Patients who have received prior radiation or cisplatin therapy exhibit more frequent myelosuppression, which is generally of greater severity (see section 4.4 and section 4.5).

Reports of thrombocytopenia after paclitaxel therapy are less frequent and less severe than neutropenia, with platelet nadir ( $<50 \times 10^9$  cells/L) observed 8 or 9 days after paclitaxel administration in 5% of patients. Haemorrhage has been reported in patients receiving paclitaxel but this does not appear to be related to thrombocytopenia. Patients (3%) may require platelet transfusions.

## **Hepatobiliary**

*Very common:* Elevated alkaline phosphatase; elevated AST; elevated ALT.

*Common:* Elevated bilirubin.

*Rare:* Hepatic necrosis (leading to death); hepatic encephalopathy (leading to death).

## **Immune System Disorders**

*Very common:* Flushing; rash.

*Common:* Dyspnoea; hypotension; chest pains; tachycardia.

*Uncommon:* Significant hypersensitivity reactions requiring therapy (e.g. Hypotension, angioneurotic oedema, bronchospasm, respiratory distress, generalised urticaria, oedema, back pains, pain in extremities, chills, diaphoresis).

## **Vascular Disorders**

*Very common:* Hypotension.

*Uncommon:* Hypertension, thrombosis, thrombophlebitis.

## **Infections and Infestation**

*Very Common:* Infection.

*Uncommon:* Septic shock.

Febrile neutropenia occurred in 5% of all courses and 30% of all courses were associated with an infectious episode. The most common infections involve the upper respiratory tract, urinary tract and blood (sepsis). In Phase II clinical trials, five septic episodes resulted in death.

## **Gastrointestinal**

*Very common:* Nausea; vomiting; diarrhoea; mucositis (these manifestations were usually mild to moderate at the recommended dose).

*Rare:* Bowel perforation (there have been several cases of bowel perforation associated with patients receiving paclitaxel. Patients receiving paclitaxel who complain of abdominal pain with other signs and symptoms, should have bowel perforation excluded).

Neutropenic enterocolitis has been reported.

## **Musculoskeletal**

*Very common:* Arthralgia; myalgia (the symptoms were usually transient occurring two to three days after paclitaxel administration and resolving within a few days).

## **Neurological**

*Very common:* Peripheral neuropathy (peripheral neuropathy occurs and is dose-dependent with 60% of patients experiencing Grade I toxicity, 10% Grade II and 2% Grade III at the recommended doses. Neuropathy was present in 87% of patients at higher doses. Severity of symptoms also increased with dose; 4% of patients experienced severe symptoms at the recommended dose versus 10% at higher doses. Neurologic symptoms may occur following the first course and symptoms may worsen with increasing exposure to paclitaxel. Peripheral neuropathy was the cause of paclitaxel discontinuation in 2% of patients. Sensory symptoms have usually improved or resolved within several months of paclitaxel discontinuation).

*Rare:* Optic nerve and/or visual disturbances (scintillating scotomata) particularly in patients who have received higher doses than recommended; these effects generally have been reversible; motor neuropathy with resultant minor distal weakness and autonomic neuropathy resulting in paralytic ileus and orthostatic hypotension.

There is a report of a grand mal seizure in a patient receiving paclitaxel and the seizure recurred after treatment with paclitaxel was recommenced. There is also a second report of a grand mal seizure in a patient with significant hepatic impairment during infusion with paclitaxel.

## **Skin and Appendages**

*Very common:* Alopecia.

*Rare:* Nail and skin changes (mild and transient); radiation-recall dermatitis; recall dermatitis.

*Local:* Phlebitis following intravenous administration has been reported. Extravasation leading to oedema, pain, erythema and induration has been reported. On occasions, extravasation can lead to cellulitis. Skin discolouration may also occur.

## **General Disorders and Administration Site Conditions**

*Very common:* Mucosal inflammation.

*Common:* Injection site reactions (including localised oedema, pain, erythema, induration, on occasion extravasation can result in cellulitis).

Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discolouration, or swelling at the injection site. These reactions have been observed more frequently with the 24 hour infusion than with the 3 hour infusion. Recurrence of skin reactions at a site of previous extravasation following administration of paclitaxel at a different site, i.e. 'recall', has been reported rarely.

Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis and fibrosis have been received as part of the continuing surveillance of paclitaxel safety. In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days.

A specific treatment for extravasation reactions is unknown at this time. Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.

Radiation pneumonitis has been reported in patients receiving concurrent radiotherapy.

## **Post-marketing experience**

The following additional adverse reactions have been identified during post-approval use of paclitaxel. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.

### **Infections and Infestations:**

Pneumonia, sepsis.

### **Cardiac Disorders:**

Atrial fibrillations, supraventricular tachycardia, reduction of left ventricle ejection fraction, ventricular failure.

**Haematological Disorders:**

Acute myeloid leukaemia, myelodysplastic syndrome.

**Immune System Disorders:**

Anaphylactic reactions (with fatal outcome), anaphylactic shock, cross-hypersensitivity between ANZATAX and other taxanes has been reported.

**Metabolism and Nutritional Disorders:**

Anorexia, tumour lysis syndrome.

**Psychiatric Disorders:**

Confusion state.

**Vascular Disorders:**

Shock.

**Respiratory, Thoracic and Mediastinal Disorders:**

Dyspnoea, pleural effusion, respiratory failure, interstitial pneumonia, lung fibrosis, pulmonary embolism, cough.

**Gastrointestinal Disorders:**

Bowel obstruction, bowel perforation, ischemic colitis, pancreatitis, mesenteric thrombosis, pseudomembranous colitis, oesophagitis, constipation, ascites.

**Neurological disorders:**

Autonomic neuropathy (resulting in paralytic ileus and orthostatic hypotension), grand mal seizures, convulsions, encephalopathy, dizziness, headache, ataxia, parasthesia, hyperesthesia.

**Eye Disorders:**

Photopsia, visual floaters, cystoid macular oedema, macular oedema.

**Ear and Labyrinth Disorders:**

Hearing loss, tinnitus, vertigo, ototoxicity.

**Skin and Subcutaneous Tissue Disorders:**

Stevens-Johnson syndrome, epidermal necrolysis, erythema multiforme, exfoliative dermatitis, urticaria, onycholysis (patients on therapy should wear sun protection on hands and feet), pruritus, rash, erythema, phlebitis, cellulitis, skin exfoliation, necrosis, fibrosis, palmar-plantar erythrodysesthesia syndrome.

## **Musculoskeletal and Connective Tissue Disorders:**

Systemic lupus erythematosus, scleroderma.

## **Investigations:**

Increase in blood creatinine.

## **General Disorders and Administration Site Conditions:**

Asthenia, malaise, pyrexia, dehydration, oedema.

## **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>.

## **4.9 Overdose**

At present there is no specific treatment for paclitaxel overdosage. In case of overdose, the patient should be closely monitored. Probable consequences of an overdose are mucositis, severe bone marrow suppression and peripheral neurotoxicity and treatment should be supportive.

Overdoses in paediatric patients may be associated with acute ethanol toxicity. Treatment is symptomatic and supportive.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

#### **Mechanism of action**

Paclitaxel is an antimicrotubule antineoplastic agent. It promotes microtubule assembly by enhancing the polymerisation of tubulin, the protein subunit of spindle microtubules, even in the absence of the mediators normally required for microtubule assembly (e.g. guanosine triphosphate [GTP]), thereby inducing the formation of stable, nonfunctional microtubules. Paclitaxel also induces abnormal arrays of “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

While the precise mechanism of action of the drug is not completely known, paclitaxel disrupts the dynamic equilibrium within the microtubule system and blocks cells in the late G2 phase and M phase of the cell cycle, inhibiting cell replication and impairing function of nervous tissue.

## 5.2 Pharmacokinetic properties

### Distribution

After paclitaxel is administered intravenously, its plasma concentration declines biphasically.

The first phase shows rapid decline representing distribution of paclitaxel to the peripheral compartment and elimination. This initial phase is followed by a relatively slow elimination of paclitaxel from the peripheral compartment.

Mean steady state volume of distribution following single dose infusion of 135 and 175 mg/m<sup>2</sup> has ranged from 198 to 688 L/m<sup>2</sup>, indicating extensive extravascular distribution and/or tissue binding.

The serum protein binding of paclitaxel is 89% following a three hour infusion of 175 mg/m<sup>2</sup> paclitaxel.

### Metabolism

The liver is thought to be the primary site of metabolism for paclitaxel.

### Excretion

In patients treated with doses of 135 and 175 mg/m<sup>2</sup> given as 3 and 24 hour infusions, mean terminal half-life has ranged from 3.0 to 52.7 hours and total body clearance has ranged from 11.6 to 24.0 L/hour/m<sup>2</sup>.

Following three hour infusions of 175 mg/m<sup>2</sup>, mean terminal half-life was estimated to be 9.9 hours; mean total body clearance was 12.4 L/hour/m<sup>2</sup>.

The mean cumulative urinary recovery of unchanged paclitaxel has been reported as 1.8 to 12.6% of the dose.

## 5.3 Preclinical safety data

### Genotoxicity

*In vitro* studies (chromosome abnormalities in human lymphocytes) and *in vivo* (micronucleus test using mice) mammalian test systems have shown paclitaxel to be mutagenic. When testing using the Ames test or the CHO/HGPRT gene mutation assay paclitaxel did not induce mutagenicity.

### Carcinogenicity

No studies have examined the carcinogenic potential of paclitaxel, however, drugs similar to paclitaxel are carcinogens.

### Reproductive and developmental toxicity

Following treatment with intravenous paclitaxel at a dose of 1 mg/kg (6 mg/m<sup>2</sup>), rats showed decreased fertility and toxicity in unborn offspring. Paclitaxel administered intravenously to

rabbits during organogenesis at a dose of 3 mg/kg (33 mg/m<sup>2</sup>) was toxic to both mother and foetus.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Citric acid

Ethanol

PEG-35 castor oil

### **6.2 Incompatibilities**

No data available.

### **6.3 Shelf life**

24 months.

### **6.4 Special precautions for storage**

Store below 25°C. Protect from light.

48 hours reconstituted stored at or below 25°C protect from light.

### **6.5 Nature and contents of container**

Anzatax Injection Concentrate is available as glass vial in single packs as 30 mg/5 mL, 100 mg/16.7 mL, 150 mg/25 mL and 300 mg/50 mL presentations.

### **6.6 Special precautions for disposal and other handling**

#### **Preparation and administration precautions**

Paclitaxel is a cytotoxic anticancer drug and as with other potentially toxic compounds, caution should be exercised in handling paclitaxel. The use of gloves is recommended. Following topical exposure, tingling, burning, redness have been observed. If paclitaxel solution contacts the skin, wash the skin immediately and thoroughly with soap and water. If paclitaxel contacts mucous membranes, the membranes should be flushed thoroughly with water. Upon inhalation, dyspnoea, chest pain, burning eyes, sore throat and nausea have been reported. Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.

#### **Handling and disposal**

The published guidelines related to procedures for the proper handling and disposal of cytotoxic drugs should be followed.

Care must be taken whenever handling cytostatic products. Always take steps to prevent exposure. This includes appropriate equipment, such as wearing gloves, and washing hands with soap and water after handling such products.

## 7. MEDICINE SCHEDULE

Prescription Medicine

## 8. SPONSOR

Pfizer New Zealand Limited  
P O Box 3998  
Auckland, New Zealand, 1140

Toll Free Number: 0800 736 363  
[www.pfizermedicalinformation.co.nz](http://www.pfizermedicalinformation.co.nz)

## 9. DATE OF FIRST APPROVAL

22 June 2000

## 10. DATE OF REVISION OF THE TEXT

28 May 2025

™ = Trademark

® = Registered trademark

### Summary table of changes

Section changed	Summary of new information
Throughout	Editorial changes
4.2, 4.4 & 4.5	Removal of Cimetidine
4.6	Safety updates for recommendations to discuss fertility preservation and for contraception duration and breastfeeding.
4.8	Updates with new ADR reporting website